Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - Clinical effect of arterial injection of ulinastatin

Hidehiko Matsukawa, Ayumi Hara, Takashi Ito, Kazuto Fukui, Koichi Sato, Masashi Ichikawa, Masahiro Yoshioka, Hiroaki Seki, Kenichi Yamataka, Ken Takizawa, Shigeo Okuda, Nobuyuki Shiraga

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate. Arterial injection (AI) of ulinastatin was performed in four cases and AI of antibiotics (IPM/CS) was done in one case, as supplemental therapies of CAI. Abdominal pain disappeared in 7.9 hours on the average, abdominal tenderness disappeared in 5.0 days and laboratory data lately recovered. All five cases treated by these therapies were cured without hemodialysis or surgical treatment in acute phase. AI of ulinastatin through arterial infusion catheter is pharmacokinetically more effective, because it yields a relatively high concentration of the drug at the acting site when compared with that of intravenous injection. Furthermore, ulinastatin inhibits different types of protease from nafamostat mesilate. Therefore the clinical effect of CAI of nafamostat mesilate is enhanced by the combined therapy with AI of ulinastatin. It is also suggested that arterial injection of ulinastatin might be effective for the control of abdominal pain and that arterial injection of antibiotics might have an advantage on prevention of infectious pancreatic necrosis.

Original languageEnglish
Pages (from-to)1229-1234
Number of pages6
JournalJapanese Journal of Gastroenterology
Volume95
Issue number11
Publication statusPublished - 1998 Nov
Externally publishedYes

Fingerprint

Protease Inhibitors
Pancreatitis
Injections
Abdominal Pain
Therapeutics
Anti-Bacterial Agents
Intravenous Injections
Renal Dialysis
urinastatin
Peptide Hydrolases
Necrosis
Catheters
Pharmaceutical Preparations
nafamostat

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - Clinical effect of arterial injection of ulinastatin. / Matsukawa, Hidehiko; Hara, Ayumi; Ito, Takashi; Fukui, Kazuto; Sato, Koichi; Ichikawa, Masashi; Yoshioka, Masahiro; Seki, Hiroaki; Yamataka, Kenichi; Takizawa, Ken; Okuda, Shigeo; Shiraga, Nobuyuki.

In: Japanese Journal of Gastroenterology, Vol. 95, No. 11, 11.1998, p. 1229-1234.

Research output: Contribution to journalArticle

Matsukawa, H, Hara, A, Ito, T, Fukui, K, Sato, K, Ichikawa, M, Yoshioka, M, Seki, H, Yamataka, K, Takizawa, K, Okuda, S & Shiraga, N 1998, 'Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - Clinical effect of arterial injection of ulinastatin', Japanese Journal of Gastroenterology, vol. 95, no. 11, pp. 1229-1234.
Matsukawa, Hidehiko ; Hara, Ayumi ; Ito, Takashi ; Fukui, Kazuto ; Sato, Koichi ; Ichikawa, Masashi ; Yoshioka, Masahiro ; Seki, Hiroaki ; Yamataka, Kenichi ; Takizawa, Ken ; Okuda, Shigeo ; Shiraga, Nobuyuki. / Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - Clinical effect of arterial injection of ulinastatin. In: Japanese Journal of Gastroenterology. 1998 ; Vol. 95, No. 11. pp. 1229-1234.
@article{e373196de52c480aac0619400b03e92c,
title = "Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - Clinical effect of arterial injection of ulinastatin",
abstract = "We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate. Arterial injection (AI) of ulinastatin was performed in four cases and AI of antibiotics (IPM/CS) was done in one case, as supplemental therapies of CAI. Abdominal pain disappeared in 7.9 hours on the average, abdominal tenderness disappeared in 5.0 days and laboratory data lately recovered. All five cases treated by these therapies were cured without hemodialysis or surgical treatment in acute phase. AI of ulinastatin through arterial infusion catheter is pharmacokinetically more effective, because it yields a relatively high concentration of the drug at the acting site when compared with that of intravenous injection. Furthermore, ulinastatin inhibits different types of protease from nafamostat mesilate. Therefore the clinical effect of CAI of nafamostat mesilate is enhanced by the combined therapy with AI of ulinastatin. It is also suggested that arterial injection of ulinastatin might be effective for the control of abdominal pain and that arterial injection of antibiotics might have an advantage on prevention of infectious pancreatic necrosis.",
author = "Hidehiko Matsukawa and Ayumi Hara and Takashi Ito and Kazuto Fukui and Koichi Sato and Masashi Ichikawa and Masahiro Yoshioka and Hiroaki Seki and Kenichi Yamataka and Ken Takizawa and Shigeo Okuda and Nobuyuki Shiraga",
year = "1998",
month = "11",
language = "English",
volume = "95",
pages = "1229--1234",
journal = "Journal of Japanese Society of Gastroenterology",
issn = "0446-6586",
publisher = "Japanese Society of Gastroenterology",
number = "11",

}

TY - JOUR

T1 - Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - Clinical effect of arterial injection of ulinastatin

AU - Matsukawa, Hidehiko

AU - Hara, Ayumi

AU - Ito, Takashi

AU - Fukui, Kazuto

AU - Sato, Koichi

AU - Ichikawa, Masashi

AU - Yoshioka, Masahiro

AU - Seki, Hiroaki

AU - Yamataka, Kenichi

AU - Takizawa, Ken

AU - Okuda, Shigeo

AU - Shiraga, Nobuyuki

PY - 1998/11

Y1 - 1998/11

N2 - We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate. Arterial injection (AI) of ulinastatin was performed in four cases and AI of antibiotics (IPM/CS) was done in one case, as supplemental therapies of CAI. Abdominal pain disappeared in 7.9 hours on the average, abdominal tenderness disappeared in 5.0 days and laboratory data lately recovered. All five cases treated by these therapies were cured without hemodialysis or surgical treatment in acute phase. AI of ulinastatin through arterial infusion catheter is pharmacokinetically more effective, because it yields a relatively high concentration of the drug at the acting site when compared with that of intravenous injection. Furthermore, ulinastatin inhibits different types of protease from nafamostat mesilate. Therefore the clinical effect of CAI of nafamostat mesilate is enhanced by the combined therapy with AI of ulinastatin. It is also suggested that arterial injection of ulinastatin might be effective for the control of abdominal pain and that arterial injection of antibiotics might have an advantage on prevention of infectious pancreatic necrosis.

AB - We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate. Arterial injection (AI) of ulinastatin was performed in four cases and AI of antibiotics (IPM/CS) was done in one case, as supplemental therapies of CAI. Abdominal pain disappeared in 7.9 hours on the average, abdominal tenderness disappeared in 5.0 days and laboratory data lately recovered. All five cases treated by these therapies were cured without hemodialysis or surgical treatment in acute phase. AI of ulinastatin through arterial infusion catheter is pharmacokinetically more effective, because it yields a relatively high concentration of the drug at the acting site when compared with that of intravenous injection. Furthermore, ulinastatin inhibits different types of protease from nafamostat mesilate. Therefore the clinical effect of CAI of nafamostat mesilate is enhanced by the combined therapy with AI of ulinastatin. It is also suggested that arterial injection of ulinastatin might be effective for the control of abdominal pain and that arterial injection of antibiotics might have an advantage on prevention of infectious pancreatic necrosis.

UR - http://www.scopus.com/inward/record.url?scp=0031793734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031793734&partnerID=8YFLogxK

M3 - Article

C2 - 9852726

AN - SCOPUS:0031793734

VL - 95

SP - 1229

EP - 1234

JO - Journal of Japanese Society of Gastroenterology

JF - Journal of Japanese Society of Gastroenterology

SN - 0446-6586

IS - 11

ER -